Global Leading Market Research Publisher QYResearch announces the release of its latest report "Anti-cancer Drug Exposure Evaluation Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global anti-cancer drug exposure evaluation services market, including market size, share, demand, industry development status, and forecasts for the next few years. For hospital pharmacists, oncology nurses, occupational health and safety officers, and clinical research organizations (CROs), the core challenge in handling antineoplastic (chemotherapy) and targeted/immuno-oncology drugs is assessing and mitigating occupational exposure risk to healthcare workers who prepare, transport, administer, or dispose of these hazardous drugs. Chronic low-level exposure to cytotoxic agents (e.g., cyclophosphamide, ifosfamide, methotrexate) has been linked to genotoxicity, reproductive toxicity, and increased cancer risk among pharmacy staff and nurses, while newer targeted therapies (e.g., tyrosine kinase inhibitors, ADCs) and immunotherapies (checkpoint inhibitors, CAR-T agents) present unknown or understudied exposure hazards. Anti-cancer drug exposure evaluation services address these pain points by providing specialized analytical testing (LC-MS/MS, HPLC, immunoassays) for surface wipe sampling (glove fingertips, countertops, floors, drug preparation isolators, patient toilets), air sampling (vapor/aerosol collection), and biological monitoring (urine metabolite analysis of healthcare workers). These services enable occupational hazard monitoring compliance with USP <800> (Hazardous Drugs—Handling in Healthcare Settings), NIOSH Alert, and OSHA guidelines, as well as providing pharmacokinetic exposure data for early-phase oncology clinical trials. As global cancer incidence rises (19.3 million new cases annually, GLOBOCAN) and more oncology drugs enter the market (over 50 new cancer drugs approved 2021–2025), demand for exposure evaluation across pharmacies, hospitals, and out-patient chemotherapy areas continues to grow. The report provides comprehensive analysis of market size, share, demand, industry development status, and forecasts for 2026–2032. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5984891/anti-cancer-drug-exposure-evaluation-services Drug Type Segmentation: Targeted Cancer Drugs, Immunotherapy Drugs, and Others The report segments the anti-cancer drug exposure evaluation services market by drug class, each with distinct analytical methodologies, regulatory scrutiny, and market growth trajectories. Targeted Cancer Drugs (≈45% of Market Value, Largest Segment) Targeted drug exposure evaluation focuses on small molecule inhibitors (tyrosine kinase inhibitors: imatinib, osimertinib, alectinib; PARP inhibitors: olaparib, niraparib; BTK inhibitors: ibrutinib) and antibody-drug conjugates (ADCs: trastuzumab deruxtecan, sacituzumab govitecan). Pharmacokinetic assessment for clinical trials (Phase I–III) requires highly sensitive LC-MS/MS methods for parent drug and metabolites in plasma/urine (lower limit of quantification 0.1–1 ng/mL). Surface wipe methods validated for cross-contamination monitoring in compounding pharmacies (USP <800> requires quarterly wipe testing). A notable user case: In Q4 2025, a large academic medical center (National Comprehensive Cancer Network member) engaged a CRO for targeted drug exposure evaluation across 9 oncology satellite pharmacies, detecting trace osimertinib on 3 surfaces (pharmacy counter, glove box, floor) despite standard cleaning protocols—leading to training remediation and increased wipe frequency from monthly to weekly. Immunotherapy Drugs (≈32% of Market Value, Fastest-Growing at CAGR 11.2%) Immunotherapy exposure evaluation covers immune checkpoint inhibitors (PD-1/PD-L1: pembrolizumab, nivolumab; CTLA-4: ipilimumab), bispecific T-cell engagers (blinatumomab), and CAR-T cell therapy vectors (viral vectors). Analytical challenges: monoclonal antibodies (large proteins, 150 kDa) require immunoassays (ELISA, MSD) not standard LC-MS, and biological monitoring in healthcare workers is less established than for small molecules. Occupational hazard monitoring for I-O drugs is rising due to NIOSH update (2024) listing 18 new immunotherapy drugs as hazardous. Syneos Health and Labcorp have developed validated ELISA panels for ipilimumab and pembrolizumab wipe testing. A user case: In Q1 2026, a European cancer center implemented semiannual exposure evaluation for nurses administering checkpoint inhibitors (8 clinics), with urine analysis for anti-drug antibodies (immune response not toxicity), baseline data establishing reference ranges. Other (≈23% of Market Value) Includes conventional cytotoxic chemotherapy (cyclophosphamide, ifosfamide, platinum agents, taxanes, anthracyclines), still widely used and regulated under USP <800>, but growth slower (CAGR 2–3%) as targeted/immunotherapies increase share. Mature analytical methods (LC-MS/MS for cyclophosphamide in urine is gold standard for biological monitoring). Application Deep Dive: Pharmacy, Hospital, Out-Patient Chemotherapy Area, and Unpackaged "Others" The report segments anti-cancer drug exposure evaluation services by healthcare setting, each with distinct exposure pathways and monitoring priorities. Pharmacy (Centralized & Satellite) (≈38% of market value, largest segment): Drug preparation areas (chemical isolators, biological safety cabinets, compounding aseptic containment isolators—CACIs). Occupational hazard monitoring for pharmacy staff (pharmacists, technicians) via surface wiping of countertops, floor, equipment handles, and PPE (glove fingertips, gown cuffs). USP <800> mandates initial wipe testing and at least every 6 months thereafter. IQVIA (Pharmacy wipe kits), Labcorp, and PPD lead. A notable user case: In Q3 2025, a US hospital system (35 pharmacies) consolidated exposure evaluation under one CRO, saving $280,000/year on fragmented testing costs; results showed higher contamination rates in satellite pharmacies (outside main pharmacy) due to less rigorous cleaning—instant corrective action. Hospital (Inpatient) (≈28% of market value, fastest-growing at CAGR 6.5%): Patient rooms (bed rails, call buttons, IV pumps, bathroom surfaces), nursing stations, medication rooms, and waste disposal areas. Occupational hazard monitoring for nurses, patient care assistants, and housekeeping staff. Surface wipe testing of high-touch areas for up to 20 different antineoplastic agents (multi-analyte panels). ICON, Parexel, and Frontage Laboratories (with hospital network contracts) active. A user case: In Q4 2025, a UK NHS trust implemented routine exposure evaluation for wards administering oral targeted therapy (patients self-administer capsules), surprising finding: toilet seats and flush handles positive for drug residues (patient urine excretion), leading to new patient education on hand hygiene and toilet flushing with lid down. Out-Patient Chemotherapy Area (≈22% of market value): Infusion chairs, IV poles, pump keypads, patient armrests, and staff handling areas (drug preparation not usually here). Pharmacokinetic assessment for clinical trials is less common; focus on occupational exposure (nurses moving between chairs). Distinguish from inpatient (no overnight stay, less variety of surfaces—PT infusions same day). Syneos Health and Celerion supply kits specific to ambulatory infusion center layout (fewer floor wipes, more armrest/chair wipe tests). Others (≈12%): Home healthcare (patients receiving oral or infused anticancer drugs at home), veterinary oncology (occupational risk for vet staff handling chemotherapy for pets), pharmacy schools (teaching lab exposure monitoring), and research laboratories handling anticancer compounds (academic). Competitive Landscape: Key Manufacturers The anti-cancer drug exposure evaluation services market is concentrated among large global CROs with specialized analytical chemistry and occupational hygiene divisions. Key suppliers identified in QYResearch's full report include: IQVIA (USA/global) – Global CRO leader; exposure evaluation kits (surface wipe) and LC-MS/MS analysis; USP <800> compliance packages.** Labcorp (USA) – Central laboratory services; biological monitoring (urine cyclophosphamide, platinum) for healthcare worker studies. PPD (USA/Thermo Fisher) – Early clinical development; exposure assessment for oncology Phase I trials (PK/PD).** ICON (Ireland/USA) – CRO; occupational exposure monitoring programs for health systems.** Parexel (USA/Germany) – Antineoplastic exposure evaluation for clinical sites (hospital and pharmacy).** Celerion (USA/Switzerland) – Early Phase (First-in-human) oncology PK studies; surface wipe validation.** Syneos Health (USA) – Real-world evidence exposure studies; targeted & immunotherapy panels. WuXi AppTec (China/USA) – Chinese CRO; exposure assessment for oncology clinical trials in Asia-Pacific. Frontage Laboratories (USA/China) – Bioanalytical services for oncology drugs (LC-MS/MS, ELISA). Exclusive Industry Observation: Analytical Sensitivity and Cross-Contamination Thresholds Unlike routine environmental monitoring (e.g., bacteria), anti-cancer drug exposure evaluation requires ultra-trace analytical sensitivity (sub-ng/cm² for surface wipes; sub-ng/mL urine for biological monitoring). A critical industry debate and service differentiator is action threshold: USP <800> recommends "trace amounts" trigger investigation but no quantitative threshold (leading to wide variation among institutions). NIOSH suggests 1 ng/cm² surface for cyclophosphamide as "alert level" based on European (German) TRGS 525 (0.1–1.0 ng/cm²). Some CROs offer multi-analyte panels with lower limit of quantitation (LLOQ) 0.01–0.05 ng/cm² (super-sensitive) but higher false positives (detects environmental contamination from previous years—non-actionable). Others set LLOQ 0.2 ng/cm² (clinically relevant based on hand-transfer models). In 2025, two CROs compared inter-lab results: Spiked wipes at 0.5 ng/cm² (6 analytes). One lab returned 0.55 ng/cm² ±0.12; second lab reported "non-detect" (<0.2 ng). The lab with higher sensitivity found up to 5× more non-compliant wipes, causing unnecessary alarm. Institutional clients now request method validation summary and historical baseline data before selecting service provider. Recent Policy and Standard Milestones (2025–2026) January 2025: USP <800> revisions (second supplement) became official, now requiring anti-cancer drug exposure evaluation including surface wipe testing for all hazardous drugs (not just antineoplastics, now including non-antineoplastic hazardous drugs like certain hormones and immunosuppressants).** May 2025: The National Institute for Occupational Safety and Health (NIOSH) added 24 new drugs to its Hazardous Drugs List (2024 update, effective 2025), including 8 targeted therapies (e.g., enfortumab vedotin, sacituzumab govitecan) and 3 immunotherapies (e.g., tebentafusp).** August 2025: The European Society of Clinical Pharmacy (ESCP) published "Guidelines for Cytotoxic Drug Exposure Monitoring in Community Pharmacies," expanding service demand beyond hospital settings. October 2025: The International Organization for Standardization (ISO) published ISO 22097:2025 "Surface wipe testing for hazardous drugs — Method validation requirements," harmonizing LLOQ, recovery, and precision criteria across CROs (adoption voluntary but expected by regulators 2027). Conclusion and Strategic Recommendation For hospital pharmacy directors, occupational health and safety officers, and clinical trial sponsors, the anti-cancer drug exposure evaluation services market provides essential occupational hazard monitoring and pharmacokinetic assessment for oncology drug handling. Targeted cancer drug testing (small molecule TKIs, ADCs) is the largest segment due to LC-MS/MS maturity and USP <800> compliance needs. Immunotherapy evaluation is fastest-growing as more mAbs and I-O agents are classified as hazardous (NIOSH updates), though analytical methods (ELISA) differ from small molecules. Pharmacies are primary application setting (centralized compounding surfaces), but hospital (inpatient) is fastest-growing as regulators expand wipe testing beyond pharmacy to patient care areas. Surface wipe testing frequency, analytical sensitivity thresholds, and multi-analyte panels are key differentiators among CROs. The full QYResearch report provides country-level consumption data by drug class and application setting, 12 supplier capability assessments (including LLOQ and multi-analyte capacity), and a 10-year innovation roadmap for anti-cancer drug exposure evaluation services integrating real-time fluorescence sensors (rather than send-out wipes) for continuous surface monitoring. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp